Single photon emission tomography with 99m technetium-methoxy-isobutyl-isonitrile for brain metastases diagnosis
Keywords:
Encephalic neoplasms, Technetium, Single photon emission computed tomographyAbstract
OBJECTIVE: To demonstrate the value of single photon emission tomography with 99m technetium-methoxy-isobutyl-isonitrile for brain metastasis diagnosis and the differentiation from an infectious lesion.
CLINICAL CASE: A 65-year-old male patient started with myoclonic focal seizures of the right upper limb. Left progressive external ophthalmoparesis was associated. A simple cranial magnetic resonance with gadolinium was performed. The characteristics of the left parietal lesions and the mesencephalon level were not conclusive to establish an etiological diagnosis. A single-photon emission tomography with 99m technetium-methoxy-isobutyl-isonitrile was indicated to clarify the nature of this lesion, which was performed at Hermanos Ameijeiras Hospital. This study showed uptake of the radiopharmaceutical in both lesions. A left temporal uptake was also found in an area that is not observed in the simple or contrasted magnetic resonance study. Considering that all the lesions captured the radiopharmaceutical, and that the uptake of this radiopharmaceutical in the brain only occurs in tumor lesions, the etiology of the lesions was diagnosed as metastatic.
CONCLUSIONS: The procedure was a useful diagnostic tool to non-invasively identify the metastatic brain lesions and avoid infectious lesions in the patient.
Downloads
References
1. Yeh R, Miloushev VZ, Ichise M. Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). En: Newton HB. Handbook of Neuro-Oncology Neuroimaging [Internet]. 2 ed. Oshio - Elsevier Ltd.; 2016 [citado: 07/04/2018]. p. 359-70. Disponible en: https://doi.org/10.1016/C2013-0-19190-8
2. Palumbo B, Buresta T, Nuvoli S, Spanu A, Schillaci O, Fravolini ML. SPECT and PET Serve as Molecular Imaging Techniques and in Vivo Biomarkers for Brain Metastases. Int J Mol Sci. 2014;(15):9878-93.
3. Omuro A, Leite C, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006;5(11):937-48.
4. León Castellón R, Cepero Llauger K, Rodríguez Rodríguez C, Castro Jiménez M, Fernández Cue L, López Díaz A, et al. SPECT cerebral con 99Tc- MIBI para discriminar entre infiltración tumoral y absceso cerebral en casos de tomografía computarizada y resonancia magnética no concluyentes. Presentación de un caso. Acta Neurol Colomb. 2016;32(1):48-53.
5. Vallabhajosula S. Molecular Imaging. Radiopharmaceuticals for PET and SPECT. Berlin: Springer-Verlag; 2009.
6. León Castellón R, López Díaz A, Martín Escuela JM, Miranda Hernández JL, Fernández Cue L, Salva Camaño. SPECT cerebral con 99m Tc- MIBI para diferenciar una lesión vascular isquémica de un tumor cerebral. Presentación de dos casos. Archivo del Hospital Universitario General Calixto García [Internet]. 2016 [citado: 12/01/2018];4(2):59-63. Disponible en: http://www.revcalixto.sld.cu/index.php/ahcg/ article/view/132
7. Ferro-Flores G, Arteaga de Murphy C. Estado actual y futuro de la gammagrafía SPECT/CT con Radiofármacos de 99mTc. Rev Invest Clin. 2007;59(5):373-81.
8. Albano D, Camoni L, Bosio G, Bertagna F. Incidental meningioma detected by using 99mTc-MIBI SPECT/CT. Rev Esp Med NuclImagen. 2017;36(5):333-4.
9. Gómez-Río M, Rodríguez-Fernández A, Ramos-Font C, López-Ramírez E, Llamas Elvira JM. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging. 2008;35(8):966-75.
10. Deltuva VP, Jurkienė N, Kulakienė I, Bunevičius A, Matukevičius A, Tamašauskas A. Introduction of novel semiquantitative evaluation of 99mTc- MIBI SPECT before and aftertreatment of glioma. Medicina (Kaunas). 2012;48(1):15-21.
11. Arbizu J, Domínguez PD, Diez-Valle R, Vigil C, García-Eulate R, Zubieta JL, et al. Neuroimagen de los tumores cerebrales. Rev Esp Med Nucl. 2011;30(1):47-65.
12. Mitsutaka F. Single-photonagents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. AnnNucl Med. 2004;18(2):79-95.
13. Shinoura N, Yamada R, Takahashi M, Nakamura O. Use of Tc-99 MIBI SPECT for characterization of metastatic brain tumors: implications for surgery. Clin Nucl Med. 2006 Sep;31(9):538-40.
14. Palumbo B, Buresta T, Nuvoli S, Spanu A, Schillaci O, Fravolini ML, Palumbo I. SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases. Int J Mol Sci. 2014 Jun 3;15(6):9878-93. doi: 10.3390/ijms15069878.
15. Alam SS, Junaid SAl, Ahmed SM. Evaluation of Technetium-99m glucoheptonate single photon emission computed tomography for brain tumor grading. Asian J Neurosurg. 2016 Apr-Jun;11(2):118-28. doi: 10.4103/1793-5482.177633.
16. Shibata Y, Yamamoto D, Takano S, Katayama W, Takeda T, Matsumura A. Direct comparison of Tl-201 and Tc-99m MIBI SPECT of glioma by a receiver operating characteristic analysis. J Clin Neurosci. 2009;16(2):264-9.
17. Karunanithi S, Bandopadhyaya GP, Sharma P, Kumar A, Singla S, Malhotra A, et al. Prospective comparison of 99mTc- GHSPECT/CT and 18F-FDOPA PET/CT for detection of recurrent glioma: a pilotstudy. Clin Nucl Med. 2014;39(2):121-8.
18. León Castellón R, Gómez Viera N, Salva Camaño S, López Díaz A, Castro Jiménez M, Martín Escuela JM. Predictores clínicos y de imagen funcional con 99Tecnecio–sestamibi para diferenciar el grado de malignidad en gliomas cerebrales. Acta Neurol Colomb. 2017;33(2):74-83.
19. De Salvo MN. Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: Diagnosis and treatment. J Radiol Case Rep. 2012 Jul;6(7):9-16.
20. Sahin S, Arisoy AS, Topkaya AE, Karsidag S. Brain-stem listeriosis: a comparison of SPECT and MRI findings. Med Gen Med. 2006;8(4):47.
21. Marner L, Henriksen O, Lundemann M, Larsen V, Law I. Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging. 2017;3(1):1-15.
22. Belliveau J, Bauman G, Macdonald D. Detecting tumor progression in glioma: current standards and new techniques. Expert Rev Anticancer Ther. 2016;16(11):1177-88.
23. Moller S, Law I, Munck Af Rosenschold P, Costa J, Poulsen H, Engelholm S. Prognostic value of 18F- FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. Radiother Oncol. 2016;121(1):132-7. doi: 10.1016/j.radonc.2016.08.014.
24. Henriksen O, Larsen V, Muhic A, Hansen A, Larsson H, Poulsen H, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F] fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med MolImag. 2016;43(1):103-12.
25. Dankbaar J, Snijders T, Robe P, Seute T, Eppinga W, Hendrikse J, et al. The use of 18F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. J Neurooncol. 2015;125(1):167-75.
26. Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C methionine PET: visual assessment versus quantitative assessment. PloS One. 2015;10(7):132-9.
